VJHemOnc Podcast

Graham Collins from Oxford University Hospitals discusses the current state of lymphoma immunotherapy research, including the efficacy of rituximab and newer treatments. Exciting upcoming data from the ECHELON-1 trial and the use of CAR T-cells are also explored.

Catherine Bollard, Stephan Ansell, and Steve Gottschalk discuss the latest advances and current challenges in immunotherapies for lymphoma, including toxicity and finding the best combinations for therapies like CAR T-cells and immune checkpoint inhibitors.

Carlo Croce, MD from Ohio State University discusses the history of CLL research, including the discovery of BCL2 gene and the role of microRNAs. He explains the advancements in targeted therapies that have revolutionized CLL treatment, focusing on the development of Venetoclase as a specific inhibitor of the BCL2 gene.

Guests Gareth Morgan, Nina Shah, and Leif Bergsagel discuss the highlights of Myeloma 2017, including MRD's impact on clinical trials, promising results of nelfinavir and proteasome inhibitor combination therapy, advancements in targeted therapies and imaging, and the consensus on primary principles of MM treatment.

Doctors Keith Stewart, Leif Bergsagel, and Gareth Morgan discuss the highlights of Myeloma 2017 meeting, including immunotherapy advances, a new MM subtype, and the use of liquid biopsies. They explore advancements in CAR-T cell therapy and combination immunotherapies, the potential for double hit myeloma, and the importance of molecular diagnostics. The podcast also touches on amyloidosis updates and advancements in multiple myeloma diagnosis and imaging.

Experts in multiple myeloma management discuss the use of MRD as primary endpoint for clinical trials, its potential as a treatment goal, and its applicability in clinical decision-making. The pros and cons of flow cytometry vs. next generation sequencing for MRD testing are explored, along with the importance of sensitivity and standardization. Available methods for managing multiple myeloma and the role of adherence in determining standardization are discussed. Efforts to standardize the use of flow in laboratories worldwide, improve reproducibility of data, and establish a quality control system are also highlighted.